RETINALAMIN

Summary

Retinalamin is a peptide bioregulator administered as injections for retinoprotective and neuroprotective treatment of retinal disease, studied almost exclusively in Russian-language reports ^[2,4]. In small human studies, repeated courses were associated with increased retinal threshold sensitivity and faster sensorimotor reaction times in glaucoma, slower progression of visual-field loss and retinal nerve-fiber-layer thinning in advanced primary open-angle glaucoma, and measurable electroretinography changes in diabetic retinopathy ^[2,3,4]. However, in an experimental photochemical-damage model in rabbits, retinalamin injections did not produce significant differences versus controls on the measured outcomes, underscoring inconsistent preclinical support ^[1]. The evidence base is limited and preliminary: studies are small, the substance has no FDA record, and effects in more advanced disease stages were often statistically nonsignificant ^[2].

Sources

1. 1. [Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas] Vestnik oftalmologii, 2021.
2. 2. [Peptide bioregulators: delivery and efficacy] Vestnik oftalmologii, 2020.
3. 3. [Neuroprotective therapy in advanced primary open-angle glaucoma] Vestnik oftalmologii, 2025.
4. 4. [Objective functional monitoring of retinoprotective treatment in diabetic retinopathy] Vestnik oftalmologii, 2024.

For educational purposes only.